Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
April 12, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal...
September 07, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
August 16, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is...
November 16, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end...
March 30, 2020 06:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
August 09, 2019 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure...
May 20, 2019 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest...
November 30, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference

- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the...
November 13, 2018 11:50 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference

- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...